Sun Pharma Advanced Research Company Limited Sun Pharma Advanced Research Company Limited

Sun Pharma Advanced Research Company Limited

SPARC

Rank in Stocks #10339
Sun Pharma Advanced Research Company Limited (SPARC), a biopharmaceutical firm... Sun Pharma Advanced Research Company Limited (SPARC), a biopharmaceutical firm established in Mumbai, India, in 2006 and operating as a subsidiary of Shanghvi Finance Private Limited, is globally committed to the discovery and advancement of innovative pharmaceutical products. The company's strategic focus involves developing novel chemical and biological entities, as well as improving existing formulations, with a key therapeutic emphasis on conditions within oncology, neurodegeneration, ophthalmology, and dermatology. SPARC currently commercializes Elepsia, a specialized levetiracetam formulation for managing epilepsy, and Xelpros, a latanoprost ophthalmic emulsion prescribed for the treatment of open-angle glaucoma or ocular hypertension. Its robust development pipeline showcases numerous candidates in various clinical trial stages: SDN-037, a difluprednate formulation in Phase 3 for addressing inflammation and pain linked to ocular surgery; PDP-716, also in Phase 3 for glaucoma; and phenobarbital sodium, targeting neonatal seizures. Additionally, the company is progressing Vodobatinib (SCO-088), which has concluded Part A of its Phase 1 study for resistant chronic myelogenous leukemia, and Vodobatinib (SCC-138), currently in Phase 2 for Parkinson's disease. Other pipeline assets include SCD-044, a Phase 2 candidate for psoriasis and atopic dermatitis, and SCO-120, advancing through Phase 1 for hormone receptor-positive, HER2-negative, metastatic breast cancer. Complementing its internal efforts, SPARC engages in strategic collaborations, including one with Bioprojet SCR to develop an S1P receptor 1 agonist for autoimmune disorders, and another with HitGen Ltd. aimed at identifying promising small molecule leads for selected therapeutic targets.
Share Price
$2.19
Last synced: 2026-11-13
Market Cap
$711.78M
Change (1 day)
-3.43%
Change (1 year)
47.62%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Trade Sun Pharma Advanced Research Company Limited (SPARC)

Category

Healthcare
Operating Margin for Sun Pharma Advanced Research Company Limited (SPARC)
Operating Margin as of November 2026 TTM: 84.26%
According to Sun Pharma Advanced Research Company Limited's latest financial reports, its current operating margin (TTM) is 84.26%. At the end of 2025 the company had an operating margin of -387.32%.
Operating Margin history for Sun Pharma Advanced Research Company Limited from 2007 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) 84.26% -121.75%
2025 -387.32% -28.89%
2024 -544.71% 481.58%
2023 -93.66% -34.72%
2022 -143.47% 148.73%
2021 -57.68% -85.93%
2020 -410.02% 392.93%
2019 -83.18% -74.04%
2018 -320.44% 342.05%
2017 -72.49% 66.68%
2016 -43.49% 61.55%
2015 -26.92% -248.81%
2014 18.09% -180.22%
2013 -22.55% -91.06%
2012 -252.20% 1,657.49%
2011 -14.35% -76.70%
2010 -61.60% 76.76%
2009 -34.85% 182.19%
2008 -12.35% -97.92%
2007 -592.84% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
19.69% -99.77%
DE
19.68% -99.77%
DE
13.26% -99.84%
JP
17.08% -99.80%
CH
10.53% -99.88%
IL
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about Sun Pharma Advanced Research Company Limited's operating margin

What is Sun Pharma Advanced Research Company Limited's operating margin?

Sun Pharma Advanced Research Company Limited's operating margin is 84.26%, as of Nov 2026.

What was Sun Pharma Advanced Research Company Limited's operating margin in 2025?

In 2025, Sun Pharma Advanced Research Company Limited's operating margin was -387.32%, compared with -544.71% in 2024.

How has Sun Pharma Advanced Research Company Limited's operating margin changed since 2020?

From 2020 to 2025, Sun Pharma Advanced Research Company Limited's operating margin was highest in 2021 (-57.68%) and lowest in 2024 (-544.71%).

How does Sun Pharma Advanced Research Company Limited's operating margin compare with similar companies?

Sun Pharma Advanced Research Company Limited's operating margin (84.26%) is higher than that of all 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with 19.69%.